专利检索 ap:("IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES" OR "ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS" OR "CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE" OR "INSTITUT GUSTAVE ROUSSY" OR "INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE" OR "UNIVERSITE DE PARIS") AND inv:"Francine COTE" 第 1 页

1.

发明申请
COMBINED USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND HEMATOPOIETIC GROWTH FACTORS FOR TREATING HEMATOPOIETIC DISEASES 有权

公开(公告)号：US20220008514A1

公开(公告)日：2022-01-13

申请号：US17297546

申请日：2019-11-28

申请人： IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES , ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT GUSTAVE ROUSSY , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE , UNIVERSITE DE PARIS

发明人： Tereza COMAN , Francine COTE , Olivier HERMINE , Guillemette FOUQUET , Julien ROSSIGNOL

IPC分类号： A61K38/20 , A61K31/138 , A61K31/343 , A61K31/135 , A61K31/4525 , A61K31/15 , A61K38/18 , A61K38/19 , A61P7/06

摘要： The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.